Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m2 vs. twice-weekly 27 mg/m2 carfilzomib (randomized A.R.R.O.W. study)
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m2 vs. twice-weekly 27 mg/m2 carfilzomib (randomized A.R.R.O.W. study)
Authors
Keywords
-
Journal
LEUKEMIA
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-05-16
DOI
10.1038/s41375-019-0480-2
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myeloma
- (2019) Heinz Ludwig et al. Blood Cancer Journal
- Patient-reported health-related quality of life from the phase III TOURMALINE-MM1 study of ixazomib-lenalidomide-dexamethasone versus placebo-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma
- (2018) Xavier Leleu et al. AMERICAN JOURNAL OF HEMATOLOGY
- Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival
- (2018) Ingemar Turesson et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study
- (2018) Sigrun Thorsteinsdottir et al. HAEMATOLOGICA
- Improvement in Overall Survival With Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
- (2018) David S. Siegel et al. JOURNAL OF CLINICAL ONCOLOGY
- Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study
- (2018) Philippe Moreau et al. LANCET ONCOLOGY
- Patient-reported outcomes in relapsed/refractory multiple myeloma: a systematic review
- (2018) Francesco Sparano et al. SUPPORTIVE CARE IN CANCER
- Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study
- (2018) Sigrun Thorsteinsdottir et al. HAEMATOLOGICA
- A systematic review of health-related quality of life in longitudinal studies of myeloma patients
- (2017) Lene Kongsgaard Nielsen et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Valuing health-related quality of life: An EQ-5D-5L value set for England
- (2017) Nancy J. Devlin et al. HEALTH ECONOMICS
- Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
- (2017) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- Instrument-Defined Estimates of the Minimally Important Difference for EQ-5D-5L Index Scores
- (2017) Nathan S. McClure et al. VALUE IN HEALTH
- Prospective longitudinal study on quality of life in relapsed/refractory multiple myeloma patients receiving second- or third-line lenalidomide or bortezomib treatment
- (2017) X Leleu et al. Blood Cancer Journal
- Health-Related Quality-of-Life Results From the Open-Label, Randomized, Phase III ASPIRE Trial Evaluating Carfilzomib, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Patients With Relapsed Multiple Myeloma
- (2016) A. Keith Stewart et al. JOURNAL OF CLINICAL ONCOLOGY
- Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
- (2016) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Philippe Moreau et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Complementary Nature of Patient-Reported Outcomes and Adverse Event Reporting in Cooperative Group Oncology Clinical Trials: A Pooled Analysis (NCCTG N0591)
- (2015) Pamela J. Atherton et al. JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
- Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
- (2015) A. Keith Stewart et al. NEW ENGLAND JOURNAL OF MEDICINE
- Understanding what matters most to people with multiple myeloma: a qualitative study of views on quality of life
- (2014) Thomas R Osborne et al. BMC CANCER
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Testing the measurement invariance of the EORTC QLQ-C30 across primary cancer sites using multi-group confirmatory factor analysis
- (2014) D. S. J. Costa et al. QUALITY OF LIFE RESEARCH
- Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients
- (2013) S K Kumar et al. LEUKEMIA
- Review of health-related quality of life data in multiple myeloma patients treated with novel agents
- (2013) P Sonneveld et al. LEUKEMIA
- Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial
- (2012) Michel Delforge et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Lenalidomide, melphalan, and prednisone, followed by lenalidomide maintenance, improves health-related quality of life in newly diagnosed multiple myeloma patients aged 65 years or older: results of a randomized phase III trial
- (2012) M. A. Dimopoulos et al. HAEMATOLOGICA
- Time associated with intravenous zoledronic acid administration in patients with breast or prostate cancer and bone metastasis
- (2012) Akshara Richhariya Cancer Management and Research
- The impact of infusion reactions associated with monoclonal antibodies in metastatic colorectal cancer: A European perspective
- (2012) Shkun Chadda et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma
- (2010) C. B. Reeder et al. BLOOD
- Efficacy and safety of once-weekly bortezomib in multiple myeloma patients
- (2010) S. Bringhen et al. BLOOD
- Evidence-Based Guidelines for Determination of Sample Size and Interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30
- (2010) Kim Cocks et al. JOURNAL OF CLINICAL ONCOLOGY
- Adverse Symptom Event Reporting by Patients vs Clinicians: Relationships With Clinical Outcomes
- (2009) Ethan Basch et al. JNCI-Journal of the National Cancer Institute
- Implications of IV monoclonal antibody infusion reaction for the patient, caregiver, and practice: results of a multicenter study
- (2008) Lee S. Schwartzberg et al. SUPPORTIVE CARE IN CANCER
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started